[./productpagepag.html]
[./indexpag.html]
[./support_pagepag.html]
[./contactpagepag.html]
Copyright © 2005 - MRC-Holland
[./indexpag.html]
Home
-
[./productpagepag.html]
Products
-
[./support_pagepag.html]
Support
-
[./article_pagepag.html]
Articles
-
[./contactpagepag.html]
contact
SALSA P004 ERBB2 / HER2-neu MLPA Kit
[http://www.geneclinics.org/profiles/hht/details.html]
Please note that P004-A1 ERBB2 old version is on available on request till March 2009. Please quote P004-A1 ERBB2 old version on your order if you don't want to receive the new improved version yet. Lot 0608: Many changes. It is now possible to distinguish a polysomy chr. 17 from a co-amplification of ERBB2 + chr. 17 centromere region. The old version P004-A1 is available on request. The ERBB2 gene, previously called Her2-neu, is a proto-oncogene located on human chromosome 17q21.1. It encodes the human epidermal growth factor receptor-2, a tyrosine kinase. This transmembrane cell surface protein is significantly over expressed in many different human cancers, among them breast, ovarian and cervical cancers. Overexpression is most often due to an increased copy number of the ERBB2 gene. This probemix P004-B1 ERRB2 contains three probes recognizing different sequences of the ERBB2 gene. In addition, it contains 21 probes for other genes on chromosome 17, including BRCA1, genes close to the centromere and genes close to ERBB2, such as TOP2A. TOP2A encodes for human topoisomerase 2. Overexpression of TOP2A, due to co-amplification with ERBB2, may influence the response of tumors to certain treatments. In addition, 6 probes targeting possibly affected genes on other chromosomes are included: two probes for EGFR, two for the ESR1 gene encoding the estrogen receptor and two for BRCA2. A deletion of either the BRCA1 and/or the BRCA2 probes indicates a genetic predisposition for breast cancer. Finally, 15 reference probes have been included, all of which are located in chromosomal regions which have been found to be silent regions in CGH experiments. However, it is possible that one or more of reference probes is altered in tumor samples. Amplification of the EGFR gene has been reported in various tumors, including breast tumors. Co-amplification of only ERBBB2 and the chromosome 17 centromere region has been observed in some samples that were expected to have polysomy 17 (based on a FISH centromere-specific probe). This SALSA MLPA kit is designed to detect gains or amplifications of one or more sequences of the ERBB2 gene and to determine the extent of the amplified region. It is possible that one or more of the reference probes are gained or lost. In addition, this kit is designed to detect deletions/duplications of one or more exons of the genes. Heterozygote deletions of probe recognition sequences should give a 35-50% reduced relative peak area of the amplification product of that probe. However, mutations and/or polymorphisms very close to the probe ligation site may result in a reduced relative peak area. Therefore, apparent deletions detected by a single probe always require confirmation by other methods. Please note that diploid and tetraploid cells can not be distinguished by MLPA as only changes in relative copy number of the sequences detected by the probes will result in a changed peak pattern.
Last change in probe mix content: Lot 0608 (January 2008) Current Lot Number.: Lot 0608
IMPORTANT NOTICE: MLPA kits are sold by MRC-Holland for research purposes and to demonstrate the possibilities of the MLPA technique. This kit is not CE/FDA certified for use in diagnostic procedures. Salsa MLPA kits are supplied with all necessary buffers and enzymes. Purchase of the Salsa MLPA test kits includes a limited license to use these products for research purposes. The use of this MLPA kit requires a thermocycler with heated lid and sequence type electrophoresis equipment. Different fluorescent PCR primers are available. The MLPA technique has been first described in Nucleic Acid Research 30, e57 (2002)
References 2006 -- Comparison of multiplex ligation dependent probe amplification to immunohistochemistry for assessing HER-2/neu amplification in invasive breast cancer. Biotech Histochem. 2006 -- Moerland E. et al. Detection of HER2 amplification in breast carcinomas: comparison of Multiplex Ligation-dependent Probe Amplification (MLPA) and Fluorescence In Situ Hybridization (FISH) combined with automated spot counting. Cell Oncol. 2006;28(4):151-9. 2003 -- Nederlof, P.M. et al. Poster: Detection of HER2 amplification by a new technique: MLPA, 2003.
[./order_infopag.html]
[./a012pag.html]
[./products_prenatal_and_postnatalpag.html]
[./products_hereditary_cancer_researchpag.html]
[./products_various_syndromespag.html]
[./products_tumor_characterisationpag.html]
[./products_mrna_analysispag.html]
[./products_methylation_specificpag.html]
[./products_otherpag.html]
[./products_pharmacogeneticspag.html]
[./mlpapricelistpag.html]
P004-B1 lot 0608 Full mix description (pdf)
[Web Creator] [LMSOFT]